Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418730 | PMC |
| http://dx.doi.org/10.1177/00185787241238305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microalbuminuria in Children With Sickle Cell Disease in the Eastern Province of Saudi Arabia.
Cureus
November 2024
College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU.
Background And Objective: Sickle cell disease (SCD) complications, such as sickle cell nephropathy (SCN), may begin in childhood and progress insidiously to chronic kidney disease in adulthood. In Saudi Arabia (SA), there is a lack of studies evaluating kidney function in children with SCD. This study aims to assess microalbuminuria (MA) as an early marker of renal dysfunction in SCD children living in the Eastern region of SA, to potentially institute appropriate early treatment.
View Article and Find Full Text PDFPrescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications.
J Clin Med
October 2024
Department of Clinical Practice, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
Hydroxyurea (HU) is an effective medication used to reduce the frequency of painful crises associated with sickle cell disease (SCD). However, data describing its prevalence among SCD patients in the Eastern Region of Saudi Arabia are scarce. This is a multi-center, retrospective, cross-sectional study that aims to investigate the pattern of prescribing HU in SCD patients and to determine the association between prescribing HU and other co-prescribed medications used to manage SCD complications.
View Article and Find Full Text PDFComment on: "Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease": Participant evaluation.
Pediatr Blood Cancer
January 2025
Department of Pediatrics, Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Irving Medical Center, New York, New York, USA.
Adherence outcomes of a liquid hydroxyurea delivery program in a pediatric population.
Pediatr Blood Cancer
December 2024
Division of Pediatric Hematology/Oncology, Boston Medical Center, Boston University Chobanian and Avedesian School of Medicine, Boston, Massachusetts, USA.
Background: Hydroxyurea remains underutilized in the pediatric sickle cell population despite its well-known efficacy in decreasing sickle cell complications and hospitalizations. Access to refills and liquid formulation remains a critical barrier to adherence to hydroxyurea regimens. This study was undertaken to determine the clinical impact of home-delivering compounded liquid hydroxyurea (LHU) to pediatric patients with sickle cell disease.
View Article and Find Full Text PDFAdherence to Hydroxyurea Therapy and its Relationship to Clinical Outcomes Among Adults Living With Sickle Cell Disease.
Hosp Pharm
October 2024
Scientific Affairs, PRIME, Charlotte, NC, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!